Biopharma & Life Sciences
Alaunos Therapeutics, Inc. Executive Compensation (FY24)
TCRT · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024 ◇ Dale Hogue | Latest say-on-pay support = July 3, 2025 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Alaunos Therapeutics, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 28, 2026Latest filing (8-K): July 10, 2025
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
111 figures on this page: 104 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
More on Alaunos Therapeutics, Inc.
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dale Hogue: $48,153 → $308,344
Say-on-pay support: 64.2% → 61.6% (2.6 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Alaunos Therapeutics, Inc.'s chief executive and what were they paid?
Dale Hogue, Interim Chief Executive Officer, received $308,344 in total compensation for fiscal 2024. Hogue's total was up from the $48,153 reported for fiscal 2023.
What was Alaunos Therapeutics, Inc.'s say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 61.6% of votes cast for or against in favor at the meeting held July 3, 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Boyle Sr. Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Drew Deniger VP, Research and Development | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Melinda Lackey SVP, Legal & Administration | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kevin Boyle Former Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Melinda Lackey Legal & Administration, Corporate Secretary | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Drew Deniger Former VP, Research and Development | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Dale Hogue Interim Chief Executive Officer | — | — | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Melinda Lackey Legal & Administration, Corporate Secretary | — | — | — | ◇ | — | — | ◇ | ◇ |
Kevin Boyle Former Chief Executive Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Dale Hogue Interim Chief Executive Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Ferdinand Groenewald Vice President, Finance | — | — | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Melinda Lackey | Option | ◇ | — | ◇ | 8/13/2034 |
| Option | ◇ | — | ◇ | 3/15/2033 | |
| Option | ◇ | — | ◇ | 12/9/2031 | |
| Option | ◇ | — | ◇ | 9/14/2032 | |
| Ferdinand Groenewald | Option | ◇ | — | ◇ | 8/13/2034 |
| Dale Hogue | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Holger Weis | ◇ | — | ◇ | — | — | — | ◇ |
Robert W. Postma | ◇ | — | ◇ | — | — | — | ◇ |
Robert J. Hofmeister | ◇ | — | ◇ | — | — | — | ◇ |
Jaime Vieser | ◇ | — | ◇ | — | — | — | ◇ |
Dale Curtis Hogue | ◇ | — | — | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Year-End symbol not shown
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | July 3, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 6, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 13, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 19, 2021 | = | ◇ | ◇ | ◇ |
| 2018 | June 13, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | September 18, 2018 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Dale Hogue (Interim Chief Executive Officer), FY2024 total compensation $308,344 (base salary $233,974) [exec_comp, SEC accession 0001193125-25-123677, filed 2025-05-21]What this page does not include
Everything above is a fact Alaunos Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Alaunos Therapeutics, Inc. sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Alaunos Therapeutics, Inc. recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
111 figures on this page: 104 cited to the filing that reported them, 7 calculated from figures it prints.
104 cited to the filing
7 calculated from the filing
Documents cited
- 0000950170-25-095029Proposal 3 - Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-25-123677Non-Employee Director Compensation · Outstanding Equity Awards at 2024 Fiscal Year-End · Summary Compensation Table
- 0000950170-24-072534Proposal 3 - Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-23-165305Proposal 3 - Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-23-115492Summary Compensation Table
- 0001193125-22-176544Proposal 3 - Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-21-169242Proposal 3 - Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-19-174799Proposal 3 – Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
- 0001193125-18-281213Proposal 3 – Advisory Vote on Executive Compensation The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Alaunos Therapeutics, Inc. executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/TCRT (accessed 2026).
Short form: data: Velarion
The paid brief for Alaunos Therapeutics, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Alaunos Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}